MAT reduces overdose deaths by 50-60%, reduces illicit drug use, and improves functioning. Yet only 18% of people with opioid use disorder who need treatment receive it. Three FDA-approved medications exist — each with different mechanisms, access pathways, and patient profiles.
| Medication | How it works | Where to get it | Best for |
|---|---|---|---|
| Suboxone (buprenorphine) | Partial opioid agonist — reduces cravings without full opioid effect | Any DEA-licensed prescriber (waiver removed 2023) Most accessible | Most people with OUD; flexible take-home doses |
| Methadone | Full opioid agonist — eliminates withdrawal and cravings completely | Federally certified OTPs only; daily clinic attendance | Severe OUD; those who haven't responded to buprenorphine; pregnancy |
| Vivitrol (naltrexone) | Opioid antagonist — blocks all opioid effects; monthly injection | Any licensed provider; must be opioid-free 7-10 days first | High motivation; post-incarceration; prefer no opioid in medication |
Since the removal of the federal prescriber waiver in 2023, any DEA-licensed prescriber can prescribe buprenorphine for OUD. It can be initiated in primary care, emergency rooms, and via telehealth. Once stabilized, many patients take it long-term — there is no evidence-based time limit. The combination with naloxone (Suboxone vs plain buprenorphine) deters injection misuse.
Methadone for OUD can only be dispensed through federally certified opioid treatment programs — daily clinic attendance required initially, with take-home doses earned over time. This structure provides the most intensive support but creates significant access barriers for working individuals and rural patients. Methadone has the longest track record and is gold standard for severe OUD and pregnancy.
Vivitrol blocks opioid receptors completely. Critical: the patient must be opioid-free for 7-10 days before initiation or precipitated withdrawal occurs. This is the most significant barrier. It is particularly useful for people leaving incarceration or completing residential treatment where opioid-free status is verified.
SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7). findtreatment.gov finds MAT providers near you. Any of the three medications is far better than no treatment — access and patient preference should drive the choice.